J&J’s Consumer Health division is bigger than most beauty and personal care multinationals. The power portfolio comprises Aveeno, Neutrogena, Johnson’s, Dr Ci: Labo, Band-Aid, Listerine and Tylenol.
In the full year 2021, these mega-brands pulled in US$14.6 billion in global sales.
In late 2021, J&J announced it would create two standalone companies. As part of its mission purpose to – Realize the Extraordinary Power of Everyday Care – the Consumer Health division will re-brand as Kenvue.
According to the multinational, the name derives from “ken” meaning knowledge, an English word mainly used in Scotland, and “vue” referencing sight. Ken is also used in other Germanic languages such as German and Dutch as part of the verb “to know”.
The new standalone entity will officially debut next year. The logo will centre on a “K” symbol and embody J&J’s unparalled reputation in scientific advancement and care dating back over 100 years.
Unveiling the Kenvue brand is a defining moment for stakeholders and an important part of the planned separation, noted Thibaut Mongon, CEO designate of Kenvue.
“We breathe life into some of the world’s most iconic and beloved brands every day, so we harnessed that same expertise, love and energy into developing our new corporate identity.”
Kenvue products are sold in more than 100 countries, including Australia, and the division will continue to be fuelled by world-class capabilities and demonstrated business momentum in the pharmacy and grocery channels.
Read the current issue of our digital magazine below:
- For more news and updates, subscribe to our weekly newsletter
- Follow us on Instagram
- Like us on Facebook
- Connect with us on LinkedIn